Antibody-modified drug-loaded microvesicle drug delivery system targeting CD206+ macrophages

By anchoring anti-CD206 monoclonal antibodies on the surface of macrophage microvesicles, precise targeting and intervention on CD206-positive macrophages is solved, and the problem of ineffectiveness of chemotherapy drugs on normal tissues and immune checkpoint inhibitors is solved. Improve the effect of tumor immunotherapy.

CN118344482BActive Publication Date: 2024-11-15TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410448071.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-15
Publication Date
2024-11-15
Estimated Expiration
2044-04-15

AI Technical Summary

Technical Problem

Among the existing tumor treatment methods, chemotherapy drugs are toxic to normal tissues and induce drug-resistant behaviors. Immune checkpoint inhibitors are ineffective in some tumor populations, especially CD206-positive macrophages inhibit immune responses in the tumor immune microenvironment, resulting in treatment. Not effective.

Method used

An anti-CD206 monoclonal antibody was developed and modified to the surface of macrophage microvesicles to achieve precise targeting and intervention on CD206-positive macrophages, through phosphatidylethanolamine-polyethylene glycol-N-hydroxyl Succinimidine ester anchoring technology enhances the specific targeting of microvesicles.

Benefits of technology

The specific identification and intervention of CD206-positive macrophages was achieved, avoiding the impact on normal macrophages, improving the effect of tumor immunotherapy, and providing more efficient drug delivery and intervention methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118344482B_ABST
    Figure CN118344482B_ABST
Patent Text Reader

Abstract

The present invention relates to a modified macrophage microvesicle of an anti-CD206 monoclonal antibody, wherein the sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 1, and the sequence of the variable region of the light chain is shown in SEQ ID NO: 2; and also relates to a drug targeting CD206-positive macrophages comprising the monoclonal antibody. The present invention provides a monoclonal antibody that accurately recognizes the extracellular segment of the macrophage mannose receptor, and uses the monoclonal antibody to modify macrophage microvesicles, thereby obtaining a drug delivery system that can specifically target M2 macrophages, thereby achieving the effect of accurate drug delivery and intervention to CD206-positive macrophages. According to preliminary experimental verification, the CD206 monoclonal antibody is stably modified on the surface of the macrophage microvesicle, and can well target CD206-positive macrophages, providing a possibility for the transformation of clinical results.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of tumor therapeutic drugs, and more particularly, relates to an anti-CD206 monoclonal antibody and an antibody-modified drug-loaded microvesicle drug delivery system targeting CD206+ macrophages. Background Art

[0002] Chemotherapy is one of the main methods of treating tumors. Since chemotherapy drugs are also toxic to normal tissues and cells, systemic use of chemotherapy drugs is extremely harmful to normal organs and tissues such as the heart, liver, and kidneys, and can also induce tumor gene mutations to produce drug resistance.

[0003] In recent years, with the rapid development of tumor immunology, biological agents such as immune checkpoint inhibitors represented by CTLA-4, PD-1 / PD-L1 and CAR-T cells have achieved encouraging results from laboratory research to clinical application. However, the survey results show that the overall response rate of a considerable number of tumor populations to the above-mentioned biological agents is only 10% to 30%, or even lower. Studies on tumor samples of non-responsive patients have shown that their tumors have more immunosuppressive cells, such as suppressive macrophages and T regulatory cells, which cannot effectively respond to immune checkpoint inhibitors. Therefore, combined tumor immunotherapy has become a promising treatment method.

[0004] CD206 is a highly glycosylated type I transmembrane protein with a molecular weight of 175 kDa, also known as mannose receptor (MR / MRC1), which consists of an extracellular segment, a membrane segment, and an intracytoplasmic segment, and is highly expressed in M2 macrophages. Studies have shown that tumor-associated macrophages with high expression of CD206 exist in large numbers in the tumor immune microenvironment, and can secrete inhibitory cytokines (IL-4 and IL-10), secrete exosomes rich in non-coding RNA, and inhibit CD8-positive T cell-mediated immune responses. In addition, CD206-positive macrophages have resistance to conventional tumor chemotherapy, and can also phagocytose immune checkpoint inhibitors such as PD-L1 antibodies, promoting tumor invasion, metastasis, and drug resistance. Therefore, precise targeted intervention of CD206-positive tumor-associated macrophages is a major breakthrough in improving the inhibitory tumor immune microenvironment and improving the anti-tumor efficacy of PD1 / PD-L1 antibodies.

[0005] Previous researchers have used mannose-modified liposomes or other nanomaterials to bind to the lectin domain on the macrophage mannose receptor, but mannose-binding proteins also exist in other parts of the body, such as CD209 expressed by dendritic cells, so the mannose-modified drug delivery system has poor specificity for CD206. Other strategies for targeting macrophages include granulocyte colony-stimulating factor CSF-1R inhibitors, CSF-1 inhibitors, CCR2 inhibitors, or macrophage depleting agents based on phagocytic function, but these methods do not have macrophage subtype selectivity, and often lead to the systemic clearance of normal macrophages and M1 anti-tumor macrophages in important organs, resulting in side effects such as neurotoxicity and cardiotoxicity. Therefore, protecting healthy tissues and normal immune cells from being affected, while achieving efficient intervention in pathogenic CD206-positive macrophages, is of great significance for tumor immunotherapy. Summary of the invention

[0006] To solve the above problems, the present invention provides an anti-CD206 monoclonal antibody, wherein the heavy chain variable region sequence is shown in SEQ ID NO:1, and the light chain variable region sequence is shown in SEQ ID NO:2.

[0007] The present invention also provides the use of the monoclonal antibody in preparing a drug targeting M2 (CD206 positive) macrophages.

[0008] The present invention also provides the use of the monoclonal antibody in preparing a reagent for detecting M2 (CD206 positive) macrophages.

[0009] The present invention also provides a drug delivery system that can target M2 (CD206 positive) macrophages, comprising a drug carrier and the above monoclonal antibody, wherein the monoclonal antibody is anchored on the surface of the drug carrier.

[0010] In a specific embodiment, the drug carrier is macrophage microvesicles.

[0011] In a specific embodiment, the monoclonal antibody is anchored to the surface of the macrophage microvesicles via phosphatidylethanolamine-polyethylene glycol-N-hydroxysuccinimide ester.

[0012] The present invention provides a monoclonal antibody that accurately recognizes the extracellular segment of the macrophage mannose receptor, and uses the monoclonal antibody to modify macrophage microvesicles, thereby obtaining a drug delivery system that can specifically target M2 macrophages, thereby achieving the effect of accurate drug delivery and intervention to CD206-positive macrophages. Preliminary experiments have verified that the CD206 monoclonal antibody is stably modified on the surface of macrophage microvesicles, and can well target CD206-positive macrophages, providing the possibility for the transformation of clinical results. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The preparation of anti-CD206 antiserum, wherein A is the SDS-PAGE detection of recombinant CD206 protein, the molecular weight of which is about 115kDa; B is the ELISA detection of the antiserum titer of 4 rats, and the OD450 value greater than 0.2 indicates effectiveness.

[0014] Figure 2 ELISA was used to detect the antibody titer of the supernatant of 14# and 17# hybridoma cell lines. An OD450 value greater than 0.2 indicated effectiveness, and the dilution multiple of the two antibodies could reach 32,000.

[0015] Figure 3 Immunofluorescence was used to detect the specific recognition and binding of CD206 antibody to M2 macrophages. Among them, CD206 antibody was co-incubated with M2 macrophages at 4℃ and 37℃ for 1h, showing that CD206 antibody binding was mainly localized on the cell membrane of M2 macrophages at 4℃, and mainly localized in the cytoplasm at 37℃. n=3-5, t-test or one-way ANOVA was used, and the data were presented as mean ± standard deviation. ns No statistical difference, **P<0.01, ***P<0.001, ****P<0.0001. Scale bar is 20μm.

[0016] Figure 4 Flow cytometry was used to detect the specific recognition and binding of CD206 antibody to M2 macrophages. n = 3-5, t-test or one-way analysis of variance was used, and the data are presented as mean ± standard deviation. ns No statistical difference, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0017] Figure 5 The CD206 antibody-modified macrophage drug-loaded microvesicles specifically bind to M2 macrophages and are internalized by the latter. Among them, A shows that CD206 antibody modification significantly increases the proportion of microvesicles internalized by M2 macrophages; B shows that CD206 antibody-modified microvesicles are internalized in the cytoplasm by M2 macrophages by immunofluorescence (DAPI-nucleus, DID-microvesicles, FITC-CD206 antibody). n = 4, t test was used, and the data are shown as mean ± standard deviation, ***P < 0.001. DETAILED DESCRIPTION

[0018] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0019] 1. Obtaining Antiserum

[0020] According to the CD206 extracellular peptide sequence, an expression vector was synthesized to express the CD206 extracellular peptide ( Figure 1 A), after purification, was used to immunize rats to obtain antiserum.

[0021] The method is as follows: 4 rats aged 5-8 weeks were prepared and the antigen was injected at multiple points on the back for immunization. For the first immunization, 100 μg of antigen was added to an equal volume of Freund's complete adjuvant and mixed and injected. For the subsequent booster immunization, 50 μg of antigen was added to an equal volume of Freund's incomplete adjuvant and mixed and injected. A total of 1 first immunization and 6 booster immunizations were performed.

[0022] After immunization, blood was collected from the rat tail vein to prepare antiserum, and the titer of antiserum was detected by indirect ELISA method. Figure 1 As shown in B, the antisera of three rats had high titers for specific binding to CD206.

[0023] 2. Obtaining hybridoma cells

[0024] One week before cell fusion, resuscitate SP2 / 0 cells and culture them normally to the logarithmic phase. Select the rats to be fused, and kill them by cervical dislocation on the day of fusion. Take the spleen, collect spleen cells and count them according to the standard procedure. Mix myeloma cells and spleen cells in a ratio of 1:3-1:10, perform cell fusion operation according to the standard procedure, and then culture them with HAT DMEM complete medium. Hybridoma cells can be seen 3 days after fusion. Change to 1 / 2HAT complete medium on the 7th day and 1 / 2HT medium on the 8th day. Screening and detection began about 10 days after fusion. Cell fusion results: After fusion, culture with HAT selective medium and observe under a microscope to see multiple growing hybridoma cells, proving that the fusion operation was successful.

[0025] Pipette 100ul / well of cell supernatant for indirect ELISA detection. According to the ELISA results, determine the positive wells. Use a single-channel pipette to pick the positive wells detected in the whole plate, conduct a second re-test, further confirm the positive wells, and perform two rounds of subcloning on the cells in the re-screened positive wells.

[0026] The monoclonal antibody subtype identification kit of Southern Biotech was used to test the subtype of each supernatant. Finally, the appropriate positive cell line and its subtype (all IgG1) were determined.

[0027] The above positive cells were expanded and cultured and injected into the peritoneal cavity of Bal b / C mice (sensitized with Freund's incomplete adjuvant). Ascites purification: The ascites of the above cells was affinity purified using a Protein A / G column. The purity of the purified CD206 antibody was greater than 90%. After testing the concentration purity, the concentration was adjusted to 2 mg / ml.

[0028] Detect the titer of monoclonal antibodies, the results are as follows Figure 2 As shown, two hybridoma cell lines (14# and 17#) with high titer were obtained.

[0029] 3. Obtaining Monoclonal Antibodies

[0030] The total RNA was extracted from the hybridoma cell lines, and the RNA was reverse transcribed into cDNA using RACE technology. The heavy chain and light chain variable region sequences were obtained by PCR amplification. The target fragment was connected to the vector using ligase, and the ligation product was transformed into E. coli competent cells, and then a single clone was picked for sequencing. The results are as follows:

[0031] The amino acid sequence of the heavy chain variable region of the 14# monoclonal antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 2; the targeting function verification of the CD206 monoclonal antibody in the following experiments is all based on the 14# monoclonal antibody.

[0032] 4. Functional validation of anti-CD206 monoclonal antibody targeting M2 macrophages

[0033] Flow cytometry and immunofluorescence techniques were used to further identify the specificity and affinity of CD206 antibodies contained in the supernatant of positive cell lines. Figure 3 and 4 As shown, CD206 antibody was co-incubated with M0 / M1 / M2 macrophages at 37°C for 1 hour, showing that CD206 antibody bound to M2 significantly more than M0 and M1 macrophages. CD206 antibody was co-incubated with M2 macrophages at 4°C and 37°C for 1 hour, respectively, showing that CD206 antibody binding was mainly localized on the cell membrane of M2 macrophages at 4°C, and mainly localized in the cytoplasm at 37°C.

[0034] 4. Construction of CD206 antibody-modified macrophage microvesicles and functional verification of their targeting to M2 macrophages

[0035] Macrophage Raw264.7 was cultured in vitro in 1640 complete medium. When the culture cell density reached more than 90%, macrophage microvesicles (MPs) were extracted. The specific operation method is to discard the supernatant of the culture dish, carefully scrape the bottom of the culture dish with a cell scraper, add 2ml of serum-free medium to wash the culture dish, and then merge 3-5 cell culture dishes into 1 dish, and starve the cells for 24h. Then irradiate ultraviolet light 38W for 1h in a sterile operating table, and then place in a 37℃ incubator overnight. The next day, all cell suspensions were collected and centrifuged in a horizontal centrifuge. Cell debris was removed by centrifugation at 4000rpm for 10min. The supernatant was placed in a 1.5ml EP tube and centrifuged at 14000rpm for 30min to collect the precipitate. The precipitate was resuspended in 1×PBS solution, the protein concentration was measured by BCA method, and the prepared macrophage microvesicles were stored in a -80℃ refrigerator for use.

[0036] The FITC-labeled CD206 antibody (anti-CD206) was amidated with the linker phosphatidylethanolamine-polyethylene glycol-N-hydroxysuccinimide ester (DSPE-PEG-NHS-2000).

[0037] Macrophage microvesicles were labeled with DID dye, stirred continuously at room temperature for 45 minutes, centrifuged at 14000rpm for 30 minutes at 4℃ to remove free DID dye, and resuspended in 1×PBS to obtain DID@MPs. F ITC@ant iCD206-PEG-DSPE was anchored on the surface of macrophage microvesicles. The DSPE end was inserted into the phospholipid bilayer of the microvesicle membrane due to hydrophobic interaction. According to the optimal antibody-modified vesicle mass ratio of 1:25-50 (ug / ul), FITC@ant iCD206-PEG-DSPE solution was added to MPs, and free anti-CD206-PEG-DSPE was removed by centrifugation. The concentrate was resuspended in 1×PBS to obtain F ITC@ant iCD206-PEG-DSPE@MPs, and flow cytometry was performed to detect FITC and DID-labeled double-positive macrophage microvesicles.

[0038] Four-week-old C57 male mice were prepared, bone marrow cells were extracted, and cultured in complete medium for 7 days to induce mature bone marrow-derived mononuclear macrophages BMDM (20% L929 cell supernatant, 10% fetal bovine serum, DMEM medium and 1% double antibody). LPS (100ng / ml) and IL-4 (25ng / ml) cytokines were used to induce BMDM into M1 and M2 macrophages, respectively. FITC@antiCD206-PEG-DSPE@MPs were added to the cells in a 12-well plate and incubated at 37℃ for 4h; 200uM / mL D-mannose was pre-treated for 4 hours as the receptor blocking experimental group. At the same time, unmodified DID@MPs were designed as a control group. Flow cytometry and immunofluorescence were used to detect the uptake of DID@MPs and FITC@anti CD206-PEG-DSPE@MPs by different subtypes of macrophages.

[0039] The results are as follows Figure 5 As shown, CD206 antibody-modified macrophage drug-loaded microvesicles specifically bind to and are internalized by M2 macrophages.

[0040] The above experiments prove that the anti-CD206 monoclonal antibody of the present invention can specifically bind to M2 macrophages, and guide the microvesicles modified by the anti-CD206 monoclonal antibody to target M2 macrophages and be internalized by the latter, thereby achieving the purpose of delivering the drug to M2 macrophages.

[0041] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An anti-CD206 monoclonal antibody, characterized in that: The heavy chain variable region sequence is shown in SEQ ID NO:1, and the light chain variable region sequence is shown in SEQ ID NO:

2.

2. Use of the monoclonal antibody according to claim 1 in the preparation of a drug targeting CD206-positive macrophages.

3. Use of the monoclonal antibody according to claim 1 in preparing a reagent for detecting CD206-positive macrophages.

4. A drug delivery system that can target CD206-positive macrophages, characterized in that: The invention comprises a drug carrier and the monoclonal antibody according to claim 1, wherein the monoclonal antibody is anchored on the surface of the drug carrier.

5. The drug delivery system according to claim 4, characterized in that The drug carrier is macrophage microvesicles.

6. The drug delivery system according to claim 5, characterized in that The monoclonal antibody is anchored on the surface of the macrophage microvesicles via phosphatidylethanolamine-polyethylene glycol-N-hydroxysuccinimide ester.

Citation Information

Patent Citations

  • Macrophage drug-loaded MP (microparticle) preparation and preparation method thereof

    CN109893515A

  • Antibody capable of binding CD206, and application thereof

    CN113512117A

  • Antibody against prorenin receptor or antigen-binding fragment of said antibody, and use of same

    WO2018084236A1